Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06412666 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
A Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT06412666 is a Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy that is actively recruiting participants, run by Cytokinetics. The registered enrollment target is 55 participants, below the 71-participant average among 8 other Pediatric trials with a reported enrollment target (23% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT06412666, a Phase 2 study of Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, is actively recruiting participants, sponsored by Cytokinetics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Aficamten
Study Locations (20)
California
- Children's Hospital Los Angeles - Los Angeles
- University of California, Los Angeles (UCLA) - Los Angeles
- UCSF Benioff Children's Hospital - San Francisco
Michigan
- University of Michigan - Ann Arbor
- Children's Hospital of Michigan - Detroit
New York
- NYP/Columbia University Medical Center - New York
- Children's Hospital at Montefiore - The Bronx
Arizona
- Phoenix Children's Hospital - Phoenix
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Hospital - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
Illinois
- Ann & Robert H. Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2030-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06412666
The ClinicalTrials.gov registry entry for NCT06412666 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 8 other Pediatric trials with a reported enrollment target (23% lower). The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pediatric appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06412666 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06412666 about?
NCT06412666 is a clinical study titled "A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).". The purpose of this study is to evaluate the efficacy, safety and PK of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
What is the current status of trial NCT06412666?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2024-05-29. Estimated completion is 2030-01.
What conditions does trial NCT06412666 study?
This clinical trial studies the following conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT06412666?
The interventions under investigation include: Placebo (DRUG), Aficamten (DRUG).
Who is sponsoring clinical trial NCT06412666?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06412666 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)
COMPLETED · Phase 2
-
Comparing Two Models of Well-Child Care for Black Families
RECRUITING · NA
-
Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia
RECRUITING · NA
-
Investigation Of Bioabsorbable Screws In Pediatric Orthopedic Surgery
RECRUITING · NA
-
Pediatric Speech Therapy Session Frequency and Speech Outcomes
ACTIVE NOT RECRUITING · NA
-
Pediatric Adhesion and New Dermal Approach Study
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.